Evidence map›Paper›PMID 36796505›Full record

ArticleThe international journal of biochemistry & cell biology2023

Secretoglobin 3A2 protects lung from developing cigarette smoke-induced pulmonary emphysema.

Reiko Kurotani, Sotaro Ono, Yuki Miyano, Shun Nakayama, Huaitian Liu, Daisuke Aibara, Satoshi Sakahara, Masamichi Sato, Kento Sato, Sumito Inoue and 4 more

Open access · greenAbstract read
In one paragraph

Article in The international journal of biochemistry & cell biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Reiko KurotaniBiochemical Engineering, Graduate School of Science and Engineering, Yamagata University, Yamagata, Japan. Electronic address: kurotanir@yz.yamagata-u.ac.jp.
Sotaro OnoBiochemical Engineering, Graduate School of Science and Engineering, Yamagata University, Yamagata, Japan.
Yuki MiyanoGenome Informatics Unit, Institute for Promotion of Medical Science Research, Yamagata University School of Medicine, Yamagata, Japan.
Shun NakayamaDepartment of Surgery, Tohoku University Graduate School of Medicine, Miyagi, Japan; Cancer Innovation Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, USA.
Huaitian LiuLaboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, USA; Laboratory of Human Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, USA.
Daisuke AibaraCancer Innovation Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, USA; Faculty of Pharmaceutical Science, Fukuoka University, Japan.
Satoshi SakaharaBiochemical Engineering, Graduate School of Science and Engineering, Yamagata University, Yamagata, Japan.
Masamichi SatoDepartment of Cardiology, Pulmonology and Nephrology, Yamagata University School of Medicine, Yamagata, Japan.
Kento SatoDepartment of Cardiology, Pulmonology and Nephrology, Yamagata University School of Medicine, Yamagata, Japan.
Sumito InoueDepartment of Cardiology, Pulmonology and Nephrology, Yamagata University School of Medicine, Yamagata, Japan.
Yoko ShibataDepartment of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan.
Maxwell P LeeLaboratory of Cancer Biology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, USA.
Hiroyuki AbeBiochemical Engineering, Graduate School of Science and Engineering, Yamagata University, Yamagata, Japan.
Shioko KimuraCancer Innovation Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, USA.
Yamagata University · JPNational Institutes of Health · USNational Cancer Institute · USFukushima Medical University · JP

Funding

Role of Novel Cytokine Secretoglobin (SCGB) 3A2 in LungZIABC010449 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KIMURA, SHIOKO · 2009 to 2025
$10.3M
Uteroglobin-Related Protein (UGRP) 1 in Lung InflammatioZ01BC010449 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI KIMURA, SHIOKO · 2002 to 2008
$594k
Intramural NIH HHS Z01 BC010449Intramural NIH HHS ZIA BC010449
6 · The paper itself

Abstract

Secretoglobin (SCGB) 3A2 is a bioactive molecule exhibiting various functions such as improving allergic airway inflammation and pulmonary fibrosis and promoting bronchial branching and proliferation during lung development. To determine if and how SCGB3A2 is involved in chronic obstructive pulmonary disease (COPD), a multifactorial disease with both airway and emphysematous lesions, a COPD mouse model was created by exposing Scgb3a2-deficient (KO), Scgb3a2-lung-specific overexpressing (TG), and wild type (WT) mice to cigarette smoke (CS) for 6 months. The KO mice showed loss of lung structure under control condition, and CS exposure resulted in more expansion of airspace and destruction of alveolar wall than WT mouse lungs. In contrast, TG mouse lungs showed no significant changes after CS exposure. SCGB3A2 increased the expression and phosphorylation of signal transducers and activators of transcription (STAT)1 and STAT3, and the expression of α1-antitrypsin (A1AT) in mouse lung fibroblast-derived MLg cells and mouse lung epithelial-derived MLE-15 cells. In MLg cells, A1AT expression was decreased in Stat3-knockdown cells, and increased upon Stat3 overexpression. STAT3 formed a homodimer when cells were stimulated with SCGB3A2. Chromatin immunoprecipitation and reporter assays demonstrated that STAT3 binds to specific binding sites on the Serpina1a gene encoding A1AT and upregulates its transcription in lung tissues of mice. Furthermore, nuclear localization of phosphorylated STAT3 upon SCGB3A2 stimulation was detected by immunocytochemistry. These findings demonstrate that SCGB3A2 protects the lungs from the development of CS-induced emphysema by regulating A1AT expression through STAT3 signaling.

Indexed as

Cigarette SmokingPulmonary Disease, Chronic ObstructivePulmonary EmphysemaPulmonary FibrosisAnimalsInflammationLungMiceSecretoglobinsScgb3a2 protein, mouseSecretoglobinsChronic obstructive pulmonary disease (COPD)LungPulmonary emphysemaSecretoglobin 3A2 (SCGB3A2)Signal transducers and activators of transcription 3 (STAT3)α1-antitrypsin

Identifiers

PMID36796505
PMCPMC10118454
OpenAlexW4320921406

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.